- $55.07m
- $208.16m
- $2.69m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 19.89 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -134.36% | ||
| Return on Equity | n/a | ||
| Operating Margin | -1190.9% | ||
Financial Summary
| Year End 31st Dec | Unit | 2013 | 2014 | 2015 | 2016 | 2017 | 2018E | 2019E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 2.23 | 2.69 | n/a | n/a | 20.33% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cibus, Inc. is an agricultural technology company that uses gene-editing technologies to develop plant traits in seeds. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits. It has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.
Directors
- Yves Ribeill NEC (61)
- Michael Carr PRE (53)
- William Koschak CFO (52)
- Gerry Nuovo SVP
- Travis Frey CTO (43)
- Debra Frimerman GCN (41)
- Laurent Arthaud DRC (58)
- Philippe Dumont IND (69)
- Jonathan Fassberg IND (55)
- Anna Kozicz-stankiewicz IND (46)
- Kimberly Nelson IND (53)
- Christopher Neugent IND (60)
- Last Annual
- December 31st, 2017
- Last Interim
- September 30th, 2018
- Incorporated
- January 8th, 2010
- Public Since
- July 20th, 2017
- No. of Shareholders
- 475
- No. of Employees
- 157
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 34,359,340
- Address
- 6455 Nancy Ridge Drive, SAN DIEGO, 92121
- Web
- https://www.cibus.com/
- Phone
- +1 8584500008
- Auditors
- BDO USA, P.C.
Upcoming Events for CBUS
Q1 2025 Cibus Inc Earnings Call
Cibus Inc Annual Shareholders Meeting
Cibus Inc Annual Shareholders Meeting
Q2 2025 Cibus Inc Earnings Release
Similar to CBUS
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the Cibus share price?
As of Today at 19:57 UTC, shares in Cibus are trading at $2.25. This share price information is delayed by 15 minutes.
How has the Cibus share price performed this year?
Shares in Cibus last closed at $2.25 and the price had moved by -86.56% over the past 365 days. In terms of relative price strength the Cibus share price has underperformed the S&P500 Index by -87.88% over the past year.
What are the analyst and broker recommendations for Cibus?
There is no consensus recommendation for this security.
Find out moreWhat is the Cibus dividend yield?
Cibus does not currently pay a dividend.
Does Cibus pay a dividend?
Cibus does not currently pay a dividend.
When does Cibus next pay dividends?
Cibus does not currently pay a dividend.
How do I buy Cibus shares?
To buy shares in Cibus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cibus?
As of the previous close price of $2.25, shares in Cibus had a market capitalisation of $55.07m.
Where are Cibus shares listed?
Here are the trading details for Cibus:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CBUS
What kind of share is Cibus?
Based on an overall assessment of its quality, value and momentum Cibus is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cibus share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Cibus share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cibus. Over the past six months, its share price has underperformed the S&P500 Index by -48.63%.
As of the last closing price of $2.25, shares in Cibus were trading -43.4% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cibus PE Ratio?
The Cibus PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.25.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cibus?
Cibus' management team is headed by:
- Yves Ribeill - NEC
- Michael Carr - PRE
- William Koschak - CFO
- Gerry Nuovo - SVP
- Travis Frey - CTO
- Debra Frimerman - GCN
- Laurent Arthaud - DRC
- Philippe Dumont - IND
- Jonathan Fassberg - IND
- Anna Kozicz-stankiewicz - IND
- Kimberly Nelson - IND
- Christopher Neugent - IND